81 related articles for article (PubMed ID: 15900905)
1. Sheep erythrocyte demonstrated better effect than IL-2 and IFN-gamma as biological response modifier against glioma in experimental model.
Sarkar S; Ghosh A; Dutta S; Roy RU; Begum Z; Mukherjee J; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2005 May; 43(5):414-9. PubMed ID: 15900905
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anti-tumor property of specific and non-specific BRMs in experimental gioma by assessing the microglial cell functional and phenotypic modulations.
Begum Z; Sarkar S; Mukherjee J; Ghosh A; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2003; 2(4):356-63. PubMed ID: 14508105
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.
Gangopaddhyay SK; Sarkar S; Begum Z; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2003 Aug; 41(8):805-13. PubMed ID: 15248476
[TBL] [Abstract][Full Text] [Related]
4. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment.
Ghosh A; Bhattacharya M; Sarkar P; Acharya S; Chaudhuri S
Indian J Exp Biol; 2010 Sep; 48(9):879-88. PubMed ID: 21506495
[TBL] [Abstract][Full Text] [Related]
5. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma in brain tumor immunotherapy.
Kane A; Yang I
Neurosurg Clin N Am; 2010 Jan; 21(1):77-86. PubMed ID: 19944968
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral infusion of interleukin-1beta and interferon-gamma induces tumor invasion with macrophages and lymphocytes in a rat glioma model.
Frewert S; Stockhammer F; Warschewske G; Zenclussen AC; Rupprecht S; Volk HD; Woiciechowsky C
Neurosci Lett; 2004 Jul; 364(3):145-8. PubMed ID: 15196664
[TBL] [Abstract][Full Text] [Related]
8. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.
Sarkar S; Begum Z; Dutta S; Dutta SK; Chaudhuri S; Chaudhuri S
J Exp Clin Cancer Res; 2002 Mar; 21(1):95-106. PubMed ID: 12071536
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and modified immunoregulation associated with IFN-gamma treatment of RG2 gliomas.
Oshiro S; Fukushima T; Tomonaga M; Black KL
Anticancer Res; 1999; 19(6B):5029-36. PubMed ID: 10697506
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.
Kim CH; Hong MJ; Park SD; Kim CK; Park MY; Sohn HJ; Cho HI; Kim TG; Hong YK
Cancer Immunol Immunother; 2006 Nov; 55(11):1309-19. PubMed ID: 16463038
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
Badn W; Hegardt P; Fellert MA; Darabi A; Esbjörnsson M; Smith KE; Janelidze S; Salford LG; Visse E; Siesjö P
Scand J Immunol; 2007 Mar; 65(3):289-97. PubMed ID: 17309784
[TBL] [Abstract][Full Text] [Related]
12. [Effect of bone marrow stromal cells transfected with interleukin 18 on growth of intracranial glioma in rats].
Li CH; Jiao BH
Ai Zheng; 2007 Jan; 26(1):38-43. PubMed ID: 17222365
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of the protein tyrosine kinase activity following interleukin-2 (IL-2), interferron gamma (IFN-gamma) and SRBC administration in brain tumor-induced conditions: SRBC acting as a dual potentiator in regulating the cytokine profile.
Bhattacharjee M; Sarkar S; Dutta S; Begum Z; Roy UR; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2004 Aug; 3(8):755-60. PubMed ID: 15197346
[TBL] [Abstract][Full Text] [Related]
14. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
17. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.
Pinto RA; Arredondo SM; Bono MR; Gaggero AA; Díaz PV
Pediatrics; 2006 May; 117(5):e878-86. PubMed ID: 16618789
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
19. Role of microglia in glioma biology.
Badie B; Schartner J
Microsc Res Tech; 2001 Jul; 54(2):106-13. PubMed ID: 11455617
[TBL] [Abstract][Full Text] [Related]
20. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Pineda B; Estrada-Parra S; Pedraza-Medina B; Rodriguez-Ropon A; Pérez R; Arrieta O
J Exp Clin Cancer Res; 2005 Dec; 24(4):575-83. PubMed ID: 16471320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
